5.0
4 Dec 2023
Current employee, more than 1 year
Cambridge, MA
Recommend
CEO approval
Business outlook
Pros
- Friendly and knowledgeable colleagues and leaders - Focus on helping patients through scientifically sound therapeutics - Strong scientific background across all levels of leadership
Cons
- Not as commercially oriented as big pharma - Financially ok for a few years but need additional revenue streams to maintain the operation - Certain decision-making and problem-solving processes are inefficient because Germany makes the final decision. US IT can't even restart the WiFi without approval and help from Germany